

# BRITISH JOURNAL OF PHARMACOLOGY

The *British Journal of Pharmacology* welcomes contributions in all fields of experimental pharmacology including neuroscience, biochemical, cellular and molecular pharmacology. The Board of Editors represents a wide range of expertise and ensures that well-presented work is published as promptly as possible, consistent with maintaining the overall quality of the journal.

## *Edited for the British Pharmacological Society by*

**A.T. Birmingham**  
(Chairman)

**R.W. Horton      W.A. Large**  
(Secretaries)

### Editorial Board

P.I. Aaronson *London*  
J.A. Angus *Melbourne, Australia*  
G.W. Bennett *Nottingham*  
T.P. Blackburn *Harlow*  
N.G. Bowery *London*  
W.C. Bowman *Glasgow*  
S.D. Brain *London*  
K.D. Butler *Horsham*  
M. Caulfield *London*  
R. Chess-Williams *Sheffield*  
T. Cocks *Melbourne, Australia*  
S.J. Coker *Liverpool*  
R.A. Coleman *Ware*  
Helen M. Cox *London*  
A.J. Cross *London*  
V. Crunelli *Cardiff*  
T.C. Cunneane *Oxford*  
F. Cunningham *London*  
A. Dickenson *London*  
J.R. Docherty *Dublin*  
A. Dray *London*  
L. Edvinsson *Lund, Sweden*  
G. Edwards *Manchester*  
J.M. Edwardson *Cambridge*  
R.M. Eglen *Palo Alto, USA*  
P.C. Emson *Cambridge*  
A.C. Foster *San Diego, USA*  
J.R. Fozard *Basle, Switzerland*  
Allison D. Fryer *Baltimore, USA*

J.P. Gallagher *Galveston, USA*  
Sheila M. Gardiner *Nottingham*  
C.J. Garland *Bristol*  
A. Gibson *London*  
M.A. Gienbycz *London*  
W.R. Giles *Calgary, Canada*  
R.G. Goldie *Perth, Australia*  
R.J. Griffiths *Connecticut, USA*  
R.W. Gristwood *Cambridge*  
Judith M. Hall *London*  
D.W.P. Hay *Philadelphia, USA*  
P.G. Hellewell *London*  
P.E. Hicks *Edinburgh*  
S.J. Hill *Nottingham*  
K. Hillier *Southampton*  
S.M.O. Hourani *Guildford*  
J.C. Hunter *Palo Alto, USA*  
E.J. Johns *Birmingham*  
R.S.G. Jones *Oxford*  
C.C. Jordan *Ware*  
P.A.T. Kelly *Edinburgh*  
D.A. Kendall *Nottingham*  
C. Kennedy *Glasgow*  
J. Leff *Loughborough*  
A.T. McKnight *Cambridge*  
C.A. Maggi *Florence, Italy*  
Janice M. Marshall *Birmingham*  
G. Martin *Beckenham*  
W. Martin *Glasgow*

A. Mathie *London*  
D.N. Middlemiss *Harlow*  
P.K. Moore *London*  
C.D. Nicholson *Oss, The Netherlands*  
H. Osswald *Tübingen, Germany*  
F.L. Pearce *London*  
J.D. Pearson *London*  
A.G. Renwick *Southampton*  
P.J. Roberts *Bristol*  
G.J. Sanger *Harlow*  
W.C. Sessa *Connecticut, USA*  
P. Sneddon *Glasgow*  
K. Starke *Freiburg, Germany*  
R.J. Summers *Melbourne, Australia*  
P.V. Taberner *Bristol*  
J. Tamargo *Madrid, Spain*  
C. Thiernemann *London*  
M.D. Tricklebank *Basle, Switzerland*  
T.J. Verbeuren *Suresnes, France*  
R.R. Vollmer *Pittsburgh, USA*  
K.J. Watling *Boston, USA*  
A.H. Weston *Manchester*  
J. Westwick *Bath*  
Eileen Winslow *Riom, France*  
E.H.F. Wong *Milan, Italy*  
B. Woodward *Bath*

### Corresponding Editors

P.R. Adams *Stony Brook, U.S.A.*  
C. Bell *Dublin*  
F.E. Bloom *La Jolla, U.S.A.*  
A.L.A. Boura *Newcastle, Australia*  
N.J. Dun *Toledo, U.S.A.*  
R.F. Furchgott *New York, U.S.A.*  
T. Godfraind *Brussels, Belgium*  
S.Z. Langer *Paris, France*

R.J. Miller *Chicago, U.S.A.*  
R.C. Murphy *Denver, U.S.A.*  
E. Muscholl *Mainz, Germany*  
R.A. North *Geneva, Switzerland*  
M. Otsuka *Tokyo, Japan*  
M.J. Rand *Melbourne, Australia*  
S. Rosell *Södertälje, Sweden*  
P. Seeman *Toronto, Canada*

L. Szekeres *Szeged, Hungary*  
B. Uvnäs *Stockholm, Sweden*  
P.A. Van Zwieten *Amsterdam, Netherlands*  
V.M. Varagić *Belgrade, Yugoslavia*  
G. Velo *Verona, Italy*  
Wang Zhen Gang *Beijing, China*  
M.B.H. Youdim *Haifa, Israel*

**Submission of manuscripts:** Manuscripts (two copies) should be sent to The Editorial Office, British Journal of Pharmacology, St. George's Hospital Medical School, Cranmer Terrace, London SW17 0RE.

Authors should consult the Instructions to Authors and the Nomenclature Guidelines for Authors in Vol. 114, 245–255. These Instructions and Guidelines also appear with the journal Index for Volumes 111–113, 1994. A checklist of the essential requirements is summarised in each issue of the journal, or as the last page of the issue.

Whilst every effort is made by the publishers and editorial committee to see that no inaccurate or misleading data, opinion or statement appears in this Journal, they and the *British Pharmacological Society* wish to make it clear that the data and opinions appearing in the articles and advertisements herein are the responsibility of the contributor or advertiser concerned. Accordingly, the *British Pharmacological Society*, the publishers and the editorial committee and their respective employees, officers and agents accept no liability whatsoever for the consequences of any such inaccurate or misleading data, opinion or statement.

The *British Journal of Pharmacology* is published by Stockton Press, a division of Macmillan Press Ltd. It is the official publication of the British Pharmacological Society.

**Scope** The *British Journal of Pharmacology* is published twice a month. It welcomes contribution in all fields of experimental pharmacology including neuroscience, biochemical, cellular and molecular pharmacology. The Board of Editors represents a wide range of expertise and ensures that well-presented work is published as promptly as possible, consistent with maintaining the overall quality of the journal.

This journal is covered by Current Contents, Excerpta Medica, BIOSIS, CABS, CINAHL and Index Medicus.

**Editorial** Manuscripts (plus two copies) and all editorial correspondence should be sent to: The Editorial Office, British Journal of Pharmacology, St George's Hospital Medical School, Cranmer Terrace, London SW17 0RE, UK. Tel: +44 (0)181 767 6765; Fax: +44 (0)181 767 5645.

**Advertisements** Enquiries concerning advertisements should be addressed to: Michael Rowley, Hasler House, High Street, Great Dunmow, Essex CM6 1AP, UK. Tel: +44 (0)1371 874613; Fax: +44 (0)1371 872273.

**Publisher** All business correspondence, supplement enquiries and reprint requests should be addressed to British Journal of Pharmacology, Stockton Press, Houndmills, Basingstoke, Hampshire RG21 2XS, UK. Tel: +44 (0)1256 29242; Fax: +44 (0)1256 810526. Publisher: Marija Vukovojac. Production Controller: Nicci Crawley.

**Subscriptions – EU/Rest of World** Subscription price per annum (3 volumes, 24 issues) £620, rest of world £820 (Airmail), £685 (Surface mail) or equivalent in any other currency. Orders must be accompanied by remittance. Cheques should be made payable to Macmillan Magazines and sent to: The Subscription Department Macmillan Press Ltd, Houndmills, Basingstoke, Hampshire RG21 2XS, UK. Where appropriate, subscribers may make payments into UK Post Office Giro Account No. 519 2455. Full details must accompany the payment. Subscribers from EC territories should add sales tax at the local rate.

**Subscriptions – USA** USA subscribers call toll free 1-800-221-2123 or send check/money order/credit card details to: Stockton Press, 49, West 24th Street, New York, NY 10010; Tel: 212 627 5757, Fax: 212 627 9256. USA annual subscription rates: \$1230 Airmail; \$1030 Surface (Institutional/Corporate); \$225 (Individual making personal payment).

*British Journal of Pharmacology* (ISSN 0007-1188) is published twice a month by Macmillan Press Ltd, c/o Mercury Airfreight International Ltd, 2323 Randolph Avenue, Avenel, NJ 07001, USA. Subscription price for institutions is \$1030 per annum (surface). 2nd class postage is paid at Rahway NJ. Postmaster: send address corrections to Macmillan Press Ltd, c/o Mercury Airfreight International Ltd, 2323 Randolph Avenue, Avenel NJ 07001.

**Reprints** of any article in this journal are available from Stockton Press, Houndmills, Basingstoke, Hampshire RG21 2XS, UK.

Tel: +44 (0)1256 29242; Fax: +44 (0)1256 810526.

**Copyright** © 1995 Stockton Press  
ISSN 0007-1188

All rights of reproduction are reserved in respect of all papers, articles, illustrations, etc., published in this journal in all countries of the world.

All material published in this journal is protected by copyright, which covers exclusive rights to reproduce and distribute the material. No material published in this journal may be reproduced or stored on microfilm or in electronic, optical or magnetic form without the written authorisation of the Publisher.

Authorisation to photocopy items for internal or personal use of specific clients, is granted by Stockton Press for libraries and other users registered with the Copyright Clearance Center (CCC) Transaction Reporting Service, provided that the base fee of \$12.00 per copy is paid directly to CCC, 21 Congress St., Salem, MA 01970, USA. 0007-1188/95 \$12.00 + \$0.00.

Apart from any fair dealing for the purposes of research or private study, or criticism or review, as permitted under the Copyright, Designs and Patent Act 1988, this publication may be reproduced, stored or transmitted, in any form or by any means, only with the prior permission in writing of the publishers, or in the case of reprographic reproduction, in accordance with the terms of licences issued by the Copyright Licensing Agency.

# **1996 Keystone Symposia**

*on Molecular and Cellular Biology*

## **The Molecular Biology of the Cardiovascular System**

*Organizers: Jeffrey M. Leiden, Victor J. Dzau, Richard Lawn, Christine Seidman,  
Robert Rosenberg and R. Sanders Williams*

*January 29-February 4, 1996; Keystone, Colorado*

**Sponsored by SmithKline Beecham Pharmaceuticals**

## **Ion Channels as Therapeutic Targets**

*Organizers: Michael Cahalan, K. George Chandy, Doug Hanson and Alan North*

*February 4-10, 1996; Tamarron, Colorado*

**Sponsored by Pfizer Inc.**

## **Neural Peptides**

*Organizers: Richard E. Mains, James F. Battey and Robert A. Steiner*

*February 8-14, 1996; Lake Tahoe, California*

## **Molecular Basis for Drug Resistance in Bacteria, Parasites and Fungi**

*Organizers: Stuart B. Levy and Thomas E. Wellems*

*March 11-17, 1996; Park City, Utah*

**Write to: Keystone Symposia • Drawer 1630 • Silverthorne, CO 80498**

**Phone: (970) 262-1230 • Fax: (970) 262-1525 • E-mail: [symposia@keystone.org](mailto:symposia@keystone.org)**

## **June 20 – 21 1996**

### **London UK**

**Festschrift in honour of Professor Sir Colin Dollery**

**International symposium – Clinical Pharmacology:  
Inflammation–Hypertension–Metabolism &  
Toxicity–Drug Regulation–Drug Development & Discovery.**

**Further information from D Boland, Department of Clinical  
Pharmacology, Royal Postgraduate Medical School,  
London W12 0NN.**

**Tel: 0181 740 3220**

**Fax: 0181 749 3439**

## PREPARATION OF MANUSCRIPTS

Authors are strongly recommended to read the full *Instructions to Authors* and *Nomenclature Guidelines for Authors* (*Br. J. Pharmacol.* 1995, **114**, 245–255) before submitting a manuscript for publication in the *British Journal of Pharmacology*. The manuscript and cover letter should be checked against the following list before mailing.

The original and one copy of the manuscript must be supplied. Manuscripts must be typed in double-line spacing on one side of A4 paper, in type not smaller than 12 characters per inch or 10 point. Both copies to include Tables and a set of labelled Figures. One set of Figures without numbers or letters is also to be included. The text to be arranged in the following subsections:

1. **Title**—To have no more than 150 characters on a separate page, which should also include a Short Title (50 characters maximum) and the name and address of the author for correspondence.
2. **Summary**—To be arranged in numbered paragraphs (Full Papers) or a single paragraph (Special Reports).—to include aims, principal results and conclusions.—to include Key words (10 maximum) at end of summary.
3. **Introduction**—To contain concise statements of the problem and the aims of the investigation.
4. **Methods**—To have brief but adequate account of the procedures; *full names of drugs (including those referred to by manufacturer's code)*, sources of drugs and statistical tests to be stated.
5. **Results**—To have no repetition of data in Figures, Tables and text.
6. **Discussion**—Findings and conclusions to be placed in context of other relevant work.  
*NB* Simple repetition of results and unwarranted speculation are not acceptable.
7. **Acknowledgements**—Sources of support. Sources of drugs not widely available commercially.
8. **References**—All references in the text to be included in the Reference List and *vice versa*. References in alphabetical order with complete citations; Journals publishing 'in press' papers identified.

*References to manuscripts submitted to other journals but not yet accepted are not allowed.*

9. **Tables**—Each on a separate page and prepared in accordance with current requirements of the Journal.
10. **Figures**—Both labelled and non-labelled Figures to be prepared in accordance with current requirements of the Journal (see *Instructions to Authors*, 1994, **114**, 245–251) and provided with Figure Number and Authors' names on back (*in pencil*).  
—each legend to be typed on a separate page and carrying keys to symbols.  
—keys to symbols and histograms must not appear on the figures themselves, but in the respective legends.  
—'box style' figures are not in keeping with the Journal style; line drawings etc must have only left-hand and bottom axes.
11. **Manuscripts**—To be accompanied by a declaration signed by each author that
  - (a) results are original
  - (b) approval of all persons concerned has been given to submit manuscripts for consideration (see also 12b)
  - (c) the same material is neither 'in press' (i.e. is in proof or has definitely been accepted for publication) nor under consideration elsewhere. Furthermore it will not be submitted or published elsewhere before a decision has been reached by the Editorial Board of the *British Journal of Pharmacology* and will not be submitted elsewhere if accepted by the *British Journal of Pharmacology*.
  - (d) Copyright assignment is included.
12. **Cover letter**—To state clearly
  - (a) Corresponding author's full postal address, telephone, telex or Fax number
  - (b) where appropriate, that *either* ethical approval has been given for investigation *or* Company or Institutional permission to publish work has been received.
13. **Reminder**—Packaging to be sufficiently robust to protect Figures and to withstand mailing.

Failure to comply with *Instructions to Authors* may lead to substantial delays in processing, review and publication and may even jeopardize acceptance of the manuscript.

## NOMENCLATURE

Authors are reminded that accepted receptor and associated terminology is laid out in *Nomenclature Guidelines for Authors*, as published in the *British Journal of Pharmacology*, *Br. J. Pharmacol.*, 1995, **114**, 253–255.

## SPECIAL REPORTS

The purpose of *Special Reports* is to provide rapid publication for **new** and **important** results which the Editorial Board considers are likely to be of special pharmacological significance. *Special Reports* will have publication priority over all other material and so authors are asked to consider carefully the status of their work before submission.

In order to speed publication there is normally no revision allowed beyond very minor typographical or grammatical corrections. If significant revision is required, the Board may either invite rapid re-submission or, more probably, propose that it be re-written as a Full Paper and be re-submitted for consideration. In order to reduce delays, proofs of *Special Reports* will be sent to authors but **essential corrections must reach the Production Office within 48 hours of receipt**. Authors should ensure that their submitted material conforms exactly to the following requirements.

*Special Reports* should normally occupy no more than two printed pages of the Journal; two illustrations (Figures or Tables, with legends) are permitted. As a guideline, with type face of 12 pitch and double-line spacing, a page of A4 paper could contain about 400 words. The absolute maximum length of the *Special Report* is 1700 words. For each Figure or Table, please deduct 200 words. The manuscript should comprise a Title page with key words (maximum of 10), a Summary consisting of a single short paragraph, followed by Introduction, Methods, Results, Discussion and References (maximum of 10). In all other respects, the requirements are the same as for Full Papers (see current 'Instructions to Authors').

## SECOND W.D.M. PATON MEMORIAL LECTURE

**E. Muscholl.** The evolution of experimental pharmacology as a biological science: the pioneering work of Buchheim and Schmiedeberg 2155

## PAPERS

**M. Barthelmebs, M. Grima & J.-L. Imbs.** Ramipril-induced decrease in renal lithium excretion in the rat 2161

**M. Barthelmebs, M. Alt-Tebacher, O. Madonna, M. Grima & J.-L. Imbs.** Absence of a losartan interaction with renal lithium excretion in the rat 2166

**A. Ahluwalia, S. Giuliani & C.A. Maggi.** Demonstration of a 'septide-sensitive' inflammatory response in rat skin 2170

**C. Brefel, E. Lazartigues, M.A. Tran, G. Gauquelin, G. Geelen, C. Gharib, J.L. Montastruc, P. Montastruc & O. Rascol.** Central cardiovascular effects of acetylcholine in the conscious dog 2175

**B.K. Kemp & T.M. Cocks.** Effects of U46619 on contractions to 5-HT, sumatriptan and methysergide in canine coronary artery and saphenous vein *in vitro* 2183

**J.R.A. Wooltorton & A. Mathie.** Potent block of potassium currents in rat isolated sympathetic neurones by the uncharged form of amitriptyline and related tricyclic compounds 2191

**S. Gupta, R.B. Moreland, R. Munarriz, J. Daley, I. Goldstein & I. Saenz de Tajada.** Possible role of Na<sup>+</sup>-K<sup>+</sup>-ATPase in the regulation of human corpus cavernosum smooth muscle contractility by nitric oxide 2201

**C. Drieu la Rochelle & S.E. O'Connor.** Sumatriptan-induced saphenous venoconstriction in the anaesthetized dog through 5-HT<sub>1</sub>-like receptor activation 2207

**J.A. Brock, E.M. McLachlan, P. Jobling & R.J. Lewis.** Electrical activity in rat tail artery during asynchronous activation of postganglionic nerve terminals by ciguatoxin-1 2213

**A.J. Reeve & A.H. Dickenson.** The role of spinal adenosine receptors in the control of acute and more persistent nociceptive responses of dorsal horn neurones in the anaesthetized rat 2221

**B. Chauvin, C. Richer & J.-F. Giudicelli.** Lack of involvement of bradykinin in the vascular sympathoinhibitory effects of angiotensin converting enzyme inhibitors in spontaneously hypertensive rats 2229

**S.M. Gardiner, J.E. March, P.A. Kemp, J.J. Mullins & T. Bennett.** Haemodynamic effects of losartan and the endothelin antagonist, SB 209670, in conscious, transgenic ((mRen-2)27), hypertensive rats 2237

**R. Abounader, J.-G. Villemure & E. Hamel.** Characterization of neuropeptide Y (NPY) receptors in human cerebral arteries with selective agonists and the new Y<sub>1</sub> antagonist BIBP 3226 2245

**M. Perretti, C. Szabó and C. Thiemermann.** Effect of interleukin-4 and interleukin-10 on leucocyte migration and nitric oxide production in the mouse 2251

**P. Hedlund, P. Alm, P. Ekström, J. Fahrenkrug, J. Hannibal, H. Hedlund, B. Larsson & K.-E. Andersson.** Pituitary adenylate cyclase-activating polypeptide, helospectin, and vasoactive intestinal polypeptide in human corpus cavernosum 2258

**K. Malarkey, E.R. Chilvers, M.F. Lawson & R. Plevin.** Stimulation by endothelin-1 of mitogen-activated protein kinases and DNA synthesis in bovine tracheal smooth muscle cells 2267

**A. Heinemann, M. Jocić, U. Holzer-Petsche, G. Pethő, B.M. Peskar, D.C. Horwell & P. Holzer.** Mediation by CCK<sub>B</sub> receptors of the CCK-evoked hyperaemia in rat gastric mucosa 2274

**P.A. Longhurst, R.E. Leggett & J.A.K. Briscoe.** Characterization of the functional muscarinic receptors in the rat urinary bladder 2279

**B.J.R. Whittle, F. László, S.M. Evans & S. Moncada.** Induction of nitric oxide synthase and microvascular injury in the rat jejunum provoked by indomethacin 2286

**Y. Wang, J.F.X. Jones, A.G. Ramage & D. Jordon.** Effects of 5-HT and 5-HT<sub>1A</sub> receptor agonists and antagonists on dorsal vagal preganglionic neurones in anaesthetized rats: an ionophoretic study 2291

**H. Tanaka, T. Minoshima & N. Endo.** The effect of a synthetic 7-thiaprostaglandin E<sub>1</sub> derivative, TEI-6122, on monocyte chemoattractant protein-1 induced chemotaxis in THP-1 cells 2298

**M. Yoneda & Y. Taché.** SMS 201-995-induced stimulation of gastric acid secretion via the dorsal vagal complex and inhibition via the hypothalamus in anaesthetized rats 2303

**R. Griffiths, J.M.C. Greiff, J. Haycock, C.D. Elton, D.J. Rowbotham & R.I. Norman.** Inhibition by halothane of potassium-stimulated acetylcholine release from rat cortical slices 2310

**R. Leurs, M.Th.M. Tulp, W.M.B.P. Menge, M.J.P. Adolfs, O.P. Zuiderveld & H. Timmerman.** Evaluation of the receptor selectivity of the H<sub>3</sub> receptor antagonists, iodophenpropit and thioperamide: an interaction with the 5-HT<sub>3</sub> receptor revealed 2315

**R.P. Waite, S.L. Lim & C.C.Y. Pang.** Effects of pinacidil on arterial and venous resistances and mean circulatory filling pressure in rats 2322

**R.P. Burt, C.R. Chapple & I. Marshall.** The role of capacitative Ca<sup>2+</sup> influx in the α<sub>1B</sub>-adrenoceptor-mediated contraction to phenylephrine of the rat spleen 2327

**D. Spina, S. Harrison & C.P. Page.** Regulation by phosphodiesterase isoenzymes of non-adrenergic non-cholinergic contraction in guinea-pig isolated main bronchus 2334